Molecular Templates, Inc.

55 articles with Molecular Templates, Inc.

• Molecular Templates, Inc. Announces Dosing of First Subject in Phase I Study of TAK-169 in Relapsed/Refractory Multiple MyelomaMilestone Triggers $10 Million Payment to Molecular Templates

  2/19/2020

  AUSTIN, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced the initiation of dosing in a Phase I study investigating TAK-169 in patients with relapsed/refractory multiple myel

• Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

  1/8/2020

  Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships

• Molecular Templates Appoints Corazon Dating Sanders, Ph.D., to its Board of Directors

  12/19/2019

  Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, announced today the appointment of Corazon “Corsee” Dating Sanders, Ph.D. to its board of directors, effective immediately.

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
• 

  ASH Roundup: Bristol-Myers Squibb, bluebird bio, Oryzon and More

  12/10/2019

  As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.

• Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting

  12/9/2019

  Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, today announced the presentations of two posters on its pipeline programs at the American Society of Hematology (ASH) 2019 Annual Meeting, taking place December 7-10, 2019 in Orlando, Florida

• Molecular Templates to Present at Two December 2019 Investor Conferences

  11/26/2019

  Molecular Templates, Inc. announced that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Evercore ISI HealthCONx Conference, and the Piper Jaffray 31st Annual Healthcare Conference.

• Molecular Templates, Inc. Announces Pricing of $50.0 Million Public Equity Offering

  11/21/2019

  Molecular Templates, Inc. announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share.

• Molecular Templates, Inc. Announces Proposed Public Equity Offering

  11/20/2019

  Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that it has commenced an underwritten public offering of its common stock and newly designated Series A convertible preferred stock.

• Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants

  11/18/2019

  Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc. (Nasdaq: MTEM; “Molecular Templates” or “MTEM”) today announced that the two companies have entered into a strategic research collaboration to discover and develop novel targeted conditioning regimens that may enhance the hematopoietic stem cell transplant process, including transplants conducted as part of treatment with ex vivo CRISPR/Cas9 gene editing therapies such as CTX001.

• Molecular Templates, Inc. Reports Third Quarter 2019 Financial Results

  11/12/2019

  As of September 30, 2019, MTEM’s cash and investments totaled $51.4 million, and is expected to fund operations through 2020.

• 

  Top 10 Cities in the U.S. for the Job Market

  1/15/2019

  New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
• 

  Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million

  9/20/2018

  Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.

• Molecular Templates Provides Corporate Update and Outlines 2018 Milestones

  1/5/2018

  A look at the past year and what's in store for Molecular Templates in 2018.

• Molecular Templates Strengthens Management Team with Appointment of Adam Cutler as Chief Financial Officer

  11/15/2017

  Mr. Cutler will report to the CEO and will be responsible for all corporate finance, accounting, and investor relations activities.

• Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)

  10/24/2017

• Molecular Templates To Ring NASDAQ Closing Bell Friday, September 1, 2017

  8/30/2017

• Takeda And Molecular Templates Announce Multi-Target Research And Licensing Collaboration To Develop Next-Generation Oncology Therapies

  8/3/2017

• Molecular Templates Completes Merger With Threshold And Private Placements

  8/2/2017

• Crippled Bay Area Pharma Threshold Rockets on Reverse Merger Deal With Molecular Templates

  3/20/2017